Table 2 Descriptive results of the long-term and follow surveys
After first vaccination Comparison of vaccines | After second vaccination Comparison of vaccination regimens | ||||||||||||||
mRNA | Vector | Homologous mRNA | Homologous vector | Heterologous | |||||||||||
BNT | 1273 | ChAd | Ad26 | BNT - BNT | 1273 – 1273 | ChAd - ChAd | ChAd - BNT | ChAd - 1273 | |||||||
LT | LT | LT | LT | LT | FU | LT | FU | LT | FU | LT | FU | LT | FU | ||
N | 2002 | 689 | 192 | 159 | 5513 | 5539 | 1378 | 1342 | 426 | 471 | 1201 | 1382 | 847 | 879 | |
Participants with SARS-CoV-2 infection after vaccination (%) | |||||||||||||||
0.6 | 0.0 | 0.5 | 1.3 | 0.5 | 1.3 | 0.4 | 0.7 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | ||
NA (n) | 9 | 2 | 1 | 1 | 14 | 1 | 1 | 0 | 0 | 1 | 6 | 6 | 4 | 4 | |
Medical consultation (%) | |||||||||||||||
Doctor’s consultation | 11.0 | 11.2 | 15.1 | 12.0 | 12.8 | 19.4 | 13.7 | 18.3 | 13.4 | 15.9 | 14.0 | 15.8 | 13.3 | 14.0 | |
Doctor’s consultation in planning | 1.8 | 2.5 | 1.0 | 4.4 | 2.4 | 2.6 | 2.7 | 3.0 | 1.2 | 2.1 | 2.6 | 2.5 | 2.2 | 2.2 | |
Hospital care | 1.6 | 1.3 | 2.6 | 0.6 | 1.7 | 2.5 | 1.1 | 2.2 | 2.6 | 2.5 | 1.1 | 1.1 | 0.7 | 1.1 | |
Hospital care in planning | 0.0 | 0.1 | 0.0 | 1.3 | 0.1 | 0.4 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | 0.4 | 0.0 | 0.0 | |
Participants with at least one medical consultation | |||||||||||||||
% | 13.0 | 13.8 | 16.7 | 16.5 | 15.4 | 21.4 | 16.5 | 21.6 | 14.8 | 18.3 | 16.8 | 18.4 | 15.7 | 16.4 | |
n | 261 | 95 | 32 | 26 | 849 | 1183 | 227 | 290 | 63 | 86 | 203 | 254 | 133 | 144 | |
Thereof: | |||||||||||||||
HPlMC was unknown to the participant (%) | |||||||||||||||
All HPlMC | 48.7 | 45.3 | 68.8 | 46.2 | 51.0 | 51.8 | 57.3 | 54.1 | 50.8 | 43.0 | 53.7 | 49.2 | 56.4 | 56.9 | |
At least one | 35.2 | 35.8 | 31.2 | 38.5 | 35.9 | 34.5 | 35.7 | 32.4 | 33.3 | 36.0 | 30.0 | 34.3 | 31.6 | 28.5 | |
Participant suspected association of HPlMC to vaccination (%) | |||||||||||||||
Regarding all HPlMC | 5.0 | 12.6 | 3.1 | 7.7 | 4.6 | 2.9 | 6.6 | 3.8 | 1.6 | 3.5 | 4.9 | 2.8 | 5.3 | 4.2 | |
Regarding at least on HPlMC | 23.0 | 17.9 | 18.8 | 23.1 | 21.9 | 17.7 | 30.8 | 19.7 | 17.5 | 10.5 | 16.7 | 16.1 | 18.8 | 18.1 | |
All HPlMC unknown and association with vaccination is suspected by the participant (%) | |||||||||||||||
4.2 | 9.4 | 3.1 | 7.6 | 3.9 | 2.4 | 5.7 | 2.8 | 1.6 | 2.3 | 4.4 | 2.4 | 5.3 | 4.2 | ||
Health problems leading to medical consultation (%) | |||||||||||||||
Musculoskeletal disorders | 36.8 | 49.5 | 34.3 | 41.9 | 39.9 | 40.3 | 43.5 | 38.3 | 49.1 | 48.7 | 38.4 | 38.9 | 38.3 | 38.2 | |
General symptoms | 42.5 | 52.6 | 31.2 | 38.1 | 42.8 | 41.9 | 57.2 | 46.9 | 34.8 | 29.0 | 33.0 | 31.5 | 33.1 | 36.1 | |
Neurological disorders | 36.4 | 44.2 | 37.4 | 34.3 | 32.4 | 29.2 | 43.1 | 30.7 | 39.6 | 26.7 | 31.5 | 26.0 | 34.6 | 29.8 | |
Cardiovascular disorders | 19.2 | 9.5 | 18.7 | 15.2 | 17.7 | 15.7 | 15.0 | 14.1 | 17.4 | 16.2 | 8.4 | 10.2 | 17.3 | 13.2 | |
Unsolicited health problems | 52.5 | 55.8 | 56.1 | 45.7 | 51.6 | 48.9 | 45.7 | 48.0 | 53.8 | 54.5 | 53.2 | 46.8 | 57.9 | 56.9 | |
No health problem named | 6.5 | 6.3 | 6.2 | 3.8 | 5.4 | 4.7 | 19.4 | 4.1 | 3.2 | 3.5 | 6.4 | 6.7 | 4.5 | 4.2 | |
After third vaccination: Comparison of vaccination regimens | |||||||||||||||
Homologous primary immunisation mRNA | Homologous primary immunisation vector | Heterologous primary immunisation mRNA/vector | |||||||||||||
BNT | 1273 | BNT | 1273 | BNT | 1273 | ||||||||||
LT | FU | LT | FU | LT | FU | LT | FU | LT | FU | LT | FU | ||||
N | 932 | 916 | 829 | 796 | 92 | 94 | 61 | 60 | 226 | 207 | 233 | 233 | |||
Participants with COVID-19 infection after vaccination (%, no missing values) | |||||||||||||||
2.4 | 26.0 | 1.9 | 22.2 | 1.1 | 23.4 | 0.0 | 23.3 | 1.8 | 24.6 | 1.7 | 24.5 | ||||
Medical consultation (%) | |||||||||||||||
Doctor’s consultation | 13.4 | 29.9 | 13.6 | 29.8 | 18.5 | 30.9 | 8.2 | 25.0 | 11.9 | 26.6 | 12.4 | 24.9 | |||
Doctor’s consultation in planning | 3.8 | 1.6 | 2.5 | 2.0 | 2.2 | 0.0 | 1.6 | 1.7 | 1.8 | 0.5 | 2.1 | 2.1 | |||
Hospital care | 1.3 | 2.7 | 1.6 | 2.3 | 5.4 | 4.3 | 0.0 | 3.3 | 1.8 | 3.9 | 0.9 | 2.1 | |||
Hospital care in planning | 0.3 | 0.1 | 0.4 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | |||
Participants with at least one medical consultation | |||||||||||||||
% | 17.4 | 31.7 | 16.9 | 32.3 | 20.7 | 31.9 | 9.8 | 26.7 | 13.7 | 29.5 | 14.6 | 27.5 | |||
n | 162 | 290 | 140 | 257 | 19 | 30 | 6 | 16 | 31 | 61 | 34 | 64 | |||
Thereof: | |||||||||||||||
HPiMC was unknown to the participant (%) | |||||||||||||||
All HPlMC | 48.1 | 50.3 | 55.0 | 56.0 | 52.6 | 70.0 | 33.3 | 43.8 | 51.6 | 55.7 | 47.1 | 60.9 | |||
At least one | 34.6 | 36.2 | 32.9 | 33.9 | 31.6 | 20.0 | 16.7 | 25.0 | 32.3 | 29.5 | 26.5 | 28.1 | |||
Participant suspected association of HPlMC to vaccination (%) | |||||||||||||||
Regarding all HPlMC | 2.5 | 2.4 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 6.5 | 1.6 | 2.9 | 0.0 | |||
Regarding at least on HPlMC | 16.7 | 10.3 | 18.6 | 14.8 | 10.5 | 13.3 | 33.3 | 6.2 | 12.9 | 6.6 | 2.9 | 0.0 | |||
All HPlMC unknown and association with vaccination is suspected by the participant (%) | |||||||||||||||
1.8 | 2.1 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 6.5 | 1.6 | 2.9 | 0.0 | ||||
Health problems leading to medical consultation (%) | |||||||||||||||
Musculoskeletal disorders | 35.8 | 41.7 | 36.4 | 35.8 | 26.3 | 33.3 | 33.5 | 25.0 | 38.8 | 44.2 | 26.5 | 29.7 | |||
General symptoms | 40.1 | 48.9 | 40.7 | 54.5 | 36.8 | 43.4 | 50.2 | 43.7 | 42.0 | 52.4 | 38.2 | 56.2 | |||
Neurological disorders | 25.9 | 31.0 | 33.5 | 32.7 | 21.0 | 30.0 | 33.5 | 31.2 | 35.5 | 29.5 | 23.5 | 25.0 | |||
Cardiovascular disorders | 21.6 | 16.5 | 15.7 | 18.3 | 5.3 | 10.0 | 16.7 | 6.2 | 12.9 | 13.1 | 8.8 | 6.2 | |||
Unsolicited health problems | 47.5 | 39.3 | 43.5 | 48.6 | 47.3 | 53.4 | 66.9 | 56.2 | 51.7 | 49.1 | 47.0 | 39.0 | |||
No health problem named | 3.1 | 6.2 | 7.9 | 2.7 | 5.3 | 0.0 | 0.0 | 6.2 | 6.5 | 1.6 | 5.9 | 3.1 | |||